We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Nene CCG area.
Paper prepared by the Royal Society for the Scientific Advisory Group for Emergencies (SAGE).
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Wolverhampton CCG area.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Tower Hamlets CCG area.
Carefully consider the benefits and risks before prescribing systemic azithromycin or other systemic macrolide antibiotics (erythromycin or clarithromycin) to patients being treated with hydroxychloroquine or chloroquine. An observational study in patients with rheumatoid arthritis has shown that co-administration of azithromycin...
Ground-breaking innovation to support medical technologies
While an urgent EU safety review evaluates reports of serious cardiovascular events and immune-mediated reactions, including autoimmune hepatitis, the use of alemtuzumab (Lemtrada) has been restricted and strengthened requirements have been introduced to monitor vital signs and liver function before...
Indication restricted to second-line treatment and contraindicated with some cardiovascular conditions and medicines Furthermore, cilostazol is now contraindicated in patients with any of the following: Unstable angina, recent myocardial infarction or coronary intervention (within 6 months) a history of severe...
Provides advice to local authority and NHS commissioners and providers about actions to improve cardiovascular disease outcomes.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
Avoid treatment with febuxostat in patients with pre-existing major cardiovascular disease (for example, myocardial infarction, stroke, or unstable angina), unless no other therapy options are appropriate. Findings from a phase 4 clinical study (the CARES study) in patients with gout...
Advice to local authority and NHS commissioners and providers about actions to improve cardiovascular disease outcomes.
Public Health England and NHS England lead coalition of over 40 organisations to step up fight against the nation’s biggest killer.
Restricted indication and new monitoring requirements.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).